Fig. 01 -

Title Slide

Fig. 02 -

Disclosures

Fig. 03 -

The Role

Fig. 04 -

Risk Groups

Fig. 05 -

Intermediate

Fig. 06 -

High Risk

Fig. 07 -

Consider SPI

Fig. 08 -

No Role

Fig. 09 -

Intermediate-Risk

Fig. 10 -

Intravesical Chemotherapy

Fig. 11 -

Differentiation

Fig. 12 -

BCG and SPI

Fig. 13 -

BCG 2nd Course

Fig. 14 -

BCG Conclusion

Fig. 15 -

Shortage of BCG

Fig. 16 -

Methylation

Fig. 17 -

Urinary IL2

Fig. 18 -

Prediction

Fig. 19 -

Group Level Prediction

Fig. 20 -

Reduction

Fig. 21 -

Options

Fig. 22 -

CUETO 98013

Fig. 23 -

Less BCG

Fig. 24 -

Combination therapy with BCG

Fig. 25 -

MMC/BCG vs BCG

Fig. 26 -

Sequential Therapy

Fig. 27 -

Therapy Differences

Fig. 28 -

Immunotherapy

Fig. 29 -

Prediction of Response

Fig. 30 -

When BCG is unavailable

Fig. 31 -

IR and no BCG

Fig. 32 -

MMC vs BCG

Fig. 33 -

Chemotherapy

Fig. 34 -

IC in High Risk

Fig. 35 -

Cochrane Review

Fig. 36 -

Taxanes

Fig. 37 -

Not the Answer

Fig. 38 -

Immunotherapy in high-risk patients when BCG is unavailable

Fig. 39 -

Immuno/Combinations

Fig. 40 -

Similar Conclusion

Fig. 41 -

KLH

Fig. 42 -

Other immunotherapy

Fig. 43 -

Immunotherapy Studies

Fig. 44 -

Phase 1 Trial

Fig. 45 -

Mistletoe Extract

Fig. 46 -

BCG Strain

Fig. 47 -

Interesting Features

Fig. 48 -

Device-assisted instillations

Fig. 49 -

EMDA with MMC

Fig. 50 -

Radio-Frequency

Fig. 51 -

TCTh

Fig. 52 -

1-Center Experience

Fig. 53 -

BCG vs TCTh

Fig. 54 -

Viable Alternative

Fig. 55 -

Slow-release treatment options

Fig. 56 -

Thermosensitive Hydrogel

Fig. 57 -

GemRIS

Fig. 58 -

Other New Strategies

Fig. 59 -

No BCG and cystectomy for high-risk patients

Fig. 60 -

Cystectomy and NMIBC

Fig. 61 -

Take Home Messages

Fig. 62 -

Thank You